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Here,  we  report  on  a  ﬁrst-in-man  trial where  the  tuberculosis  (TB)  vaccine  Ag85B-ESAT-6  (H1)  was  adju-
vanted  with  escalating  doses  of  a novel  liposome  adjuvant  CAF01.  On  their  own,  protein  antigens  cannot
sufﬁciently  induce  immune  responses  in  humans,  and  require  the  addition  of  an  adjuvant  system  to
ensure appropriate  delivery  and  concomitant  immune  activation.  To date  no  approved  adjuvants  are
available  for  induction  of  cellular  immunity,  which  seems  essential  for  a  number  of vaccines,  includ-
ing  vaccines  against  TB.  We  vaccinated  four  groups  of  human  volunteers:  a  non-adjuvanted  H1  group,
followed  by  three  groups  with escalating  doses  of  CAF01-adjuvanted  H1  vaccine.  All  subjects were  vacci-
nated  at 0  and  8 weeks  and  followed  up for 150  weeks.  Vaccination  did  not  cause  local  or systemic  adverselinical trial
djuvant
mmunogenicity
effects  besides  transient  soreness  at the injection  site.  Two  vaccinations  elicited  strong  antigen-speciﬁc
T-cell  responses  which  persisted  after  150  weeks  follow-up,  indicating  the  induction  of a  long-lasting
memory  response  in the  vaccine  recipients.  These  results  show  that  CAF01  is  a safe  and  tolerable,  Th1-
inducing  adjuvant  for human  TB  vaccination  trials  and  for vaccination  studies  in  general  where  cellular
immunity  is required.
ublis©  2014  The  Authors.  P
. Introduction
Tuberculosis (TB) is caused by Mycobacterium tuberculosis
MTB). A third of the world’s population is infected with MTB, in
013 there was a global estimated 8.6 million cases of TB and 1.3
illion deaths caused by this pathogen [1]. Currently, the onlyvailable vaccine against TB is bacillus Calmette-Guérin (BCG), a
ive attenuated vaccine derived from Mycobacterium bovis. BCG pro-
ects against severe forms of childhood TB but its efﬁcacy against
ulmonary TB in adults is highly variable. Therefore, there is an
rgent need for second generation TB vaccines [2,3].
∗ Corresponding author at: Leiden University Medical Center (LUMC), Department
f  Infectious Diseases, C5P, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
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ax:  +45 3268 3035.
E-mail addresses: j.t.van dissel@lumc.nl (J.T. van Dissel), PA@ssi.dk (P. Andersen).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.036
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Several novel vaccines are being explored, among which a
prime-boost strategy using new TB vaccine candidates to boost
BCG is considered a promising strategy [4]. In a recent phase IIb
trial, an experimental vaccine MVA85A (modiﬁed vaccinia virus
Ankara expressing antigen 85A) was  given to infants who had pre-
viously been BCG-vaccinated, however the MVA85A vaccine failed
to demonstrate efﬁcacy against TB infection as well as TB disease
emphasizing that there is a continued need for developing and test-
ing novel vaccination strategies against TB [5]. We  have published
two human clinical trials investigating the Hybrid 1(H1) subunit
vaccine; based on the hybrid protein of Early Secretory Antigenic
Target (ESAT-6) and Antigen 85B (Ag85B) adjuvanted with IC31®
(H1:IC31) [6,7]. These reports demonstrated that the H1:IC31 vac-
cine was  safe and generated long-lasting antigen-speciﬁc Th1 T-cell
responses against the hybrid protein [6,7].Here we  report on an independent H1 TB vaccine trial in which
the adjuvant IC31® is replaced by the CAF01 adjuvant. CAF01
is a novel two-component liposomal adjuvant system composed
of a cationic liposome vehicle (dimethyldioctadecyl-ammonium
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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DDA)) stabilized with a glycolipid immunomodulator (trehalose
,6-dibehenate (TDB)) which is a synthetic variant of cord fac-
or located in the mycobacterial cell wall. In addition to acting as
n immunomodulator, TDB also ensures long-term stability of the
DA liposomes. Based on immunological data as well as physico-
hemical stability data the optimal weight ratio of DDA to TDB was
ound to be 5:1 [8]. In animal models, CAF01 promotes a broad
nd complex immune response characterized by multifunctional
-cells with a Th1 proﬁle and possesses the same ability to induce
ong-lived immune responses as IC31® presumably through the
stablishment of a vaccine depot [8–13]. In preclinical studies,
AF01 also induced a Th17 response due to TDB signaling through
he C-type lectin receptor Mincle [14]. CAF01 adjuvanted H1 vac-
ine was protective in animal models of TB [11–13,15], but safety
nd immunogenicity of a CAF01-adjuvanted vaccine has not yet
een assessed in humans.
We  report herein the ﬁrst phase I clinical trial in human
olunteers employing a CAF01-adjuvanted subunit TB vaccine
H1:CAF01), with safety as primary endpoint. The secondary objec-
ive of the trial was to evaluate the immunogenicity of H1:CAF01
n humans.
. Materials and methods
An elaborated description of materials and methods can be
ound in the online supplement.
.1. Ethics statement
All subjects volunteered to participate in the clinical trial and
ave informed consent after verbal and written information was
rovided. The trial protocol (EUDRACT No.: 2008-006003-23, Clin-
calTrials.gov Identiﬁer: NCT00922363, LUMC protocol: P09.111),
he Investigator’s Brochure and the Investigational Medicinal Prod-
ct Dossier were following good clinical practice (GCP) and the
eclaration of Helsinki and were approved by the accredited Ethical
eview Board of LUMC and the relevant national authorities.
.2. The investigational vaccine
CAF01 is a two-component liposomal adjuvant system devel-
ped by SSI [16,8,9,10]. One component, DDA, is a cationic
uaternary ammonium salt and the other component, TDB, is a gly-
olipid. Both components are synthetically manufactured. When
hese two components are mixed and rehydrated in the speciﬁc
eight ratio 5:1, DDA to TDB, the liposomal adjuvant is named
AF01. The H1 recombinant fusion protein of Ag85B and ESAT-6, is
eveloped and manufactured by Statens Serum Institut (SSI, Copen-
agen, Denmark). H1 sterile solution and CAF01 sterile suspension
ere manufactured by SSI, in an accredited GMP  facility and sup-
lied to the LUMC pharmacy in separate vials of relevant strengths.
he vaccine was reconstituted by addition of the speciﬁed volume
f adjuvant to the antigen concentrate, and injected into the deltoid
uscle with a 25 mm 22–25 Gauge needle in a volume of 0.5 ml.
.3. Trial design
The trial was an open label, single-center, non-randomized
hase I exploratory trial in mycobacteria-naïve individuals deﬁned
y a negative TST (<10 mm,  2 units RT-23 PPD (SSI, Denmark))
nd a negative Quantiferon®-TB Gold In-Tube test (QFT; Qia-
en, Venlo, The Netherlands). All individuals were HIV negative.
he trial comprised four vaccination groups. Subjects in group
 received 50 g H1 with no adjuvant, whereas groups 2–4
eceived the same amount of antigen with 125/25 g, 313/63 g
nd 625/125 g CAF01, respectively. In all vaccination groups, the 32 (2014) 7098–7107 7099
subjects were vaccinated on trial days 0 and 56. After the orig-
inal trial was  completed, a protocol amendment was  approved
(CCMO 12.1306/MA/26270, NL26270.000.09) and all trial partic-
ipants were invited to attend a long-term visit 150 weeks after
initial enrolment. Long-term visits were successfully conducted for
31 out of the original 34 volunteers that received 2 vaccinations
within the appropriate time window. Timing of the long-term visit
was on average 150.7 weeks (median 152.1 weeks; range 123–167
weeks) post primary vaccination and is referred to as ‘150 weeks’
throughout the manuscript.
2.4. Trial subjects
The trial population consisted of 38 volunteers, healthy adult
females or males between 18 and 55 years of age who had not been
BCG vaccinated and who  did not have active, chronic or past TB
disease, and who had no MTB  infection as conﬁrmed by a nega-
tive QFT and a negative TST at screening. The general health of all
participants was assessed by reviewing their recorded medical his-
tory, and performing a physical examination, and standard blood
(including hepatitis B, hepatitis C and HIV testing) and urine tests.
The volunteers were ﬁnancially compensated as approved by
the Institutional Review Board for the number and amount of blood
and urine samples, inconvenience with respect to the intramus-
cular administration and for the time spent on trial visits and
transportation to the trial site.
2.5. Safety parameters
The subjects remained under medical observation for 3 h after
each intramuscular vaccination, for possible immediate adverse
reactions. During the ﬁrst week after each vaccination, symptoms
and evening armpit temperature were recorded on a daily basis,
thereafter on a weekly basis. A medical examination of local adverse
reactions and temperature was performed on days 0, 1, 7 and 42
after both vaccinations.
Adverse events were coded into system organ class (SOC) and
preferred terms (PT) according to MedDRA version 10.0 and were
classiﬁed into local (loco-regional) and systemic adverse events.
The intensity of adverse events was  graded as mild (grade 1/eas-
ily tolerated), moderate (grade 2/sufﬁcient to interfere with daily
activities) or severe (grade 3/preventing normal activity).
The relatedness of adverse events to the vaccination was graded
as not related, possibly related, probably related or certainly
related. Abnormal laboratory ﬁndings were scored for severity into
severity grades 1–4 (based on “Toxicity grading scale for healthy
adults and adolescent volunteers enrolled in preventive vaccine
clinical trials” – FDA 2007 guidelines).
2.6. Quantiferon®-TB Gold In-Tube test
QFT testing was  done according to the manufacturer’s instruc-
tions and categorized as positive when the result was  ≥0.35 IU/ml
at baseline, and at 32 and 150 weeks after the primary vaccination.
2.7. PBMC isolation and immunogenicity parameters
Blood samples for cellular immunity and antibody determina-
tions were collected at baseline and at 1 and 6 weeks after both
vaccinations, and at weeks 32, 52 and 150 post the primary vaccina-
tion. Brieﬂy, 40 ml  heparinized blood was  centrifuged on Leucosep
tubes (Greiner-bio-one, Austria) containing 15 ml  Ficoll (LUMC
pharmacy #902861) (20 min/800 g), after centrifugation plasma
was removed for storage at −70 ◦C and PBMCs were removed and
washed three times with sterile PBS (LUMC pharmacy). PBMCs
were aliquoted and stored in liquid nitrogen in RPMI (Invitrogen
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22409-015) containing 20% fetal calf serum (PAA Laboratories
A15-043, Netherlands)/10% DMSO (Sigma #41650). After defrost-
ng a minimum PBMC viability of 80% was considered acceptable
or assay purposes.
.8. Flow cytometry
PBMCs were stimulated with pools from Ag85B or ESAT-6 pep-
ides for 6 h or left unstimulated before staining for CD3, CD4, CD14,
D19, CD45RO, IFN-, IL-2, TNF-, IL-22, IL-17A and CD154 (see
nline supplement) [18].
.9. Quantifying IFN- producing cells
IFN- was determined using ELISpot from frozen samples to
nable batch processing of longitudinally collected samples [19,20].
n this protocol, cells were thawed and pre-stimulated for 16–18 h,
ollowed by 24 h incubation in the ELISpot plate [10] (see online
upplement).
.10. Multiplex analysis of cytokine release
PBMCs were stimulated 6 days with H1 fusion protein and a
anel comprising cytokines (IFN-, IL-2, IL-4, IL-10, IL-13, IL-17A,
L-22, TNF-), chemokines (IP-10, MIG, MCP-1, MIP-1b) and growth
actors (VEGF and GM-CSF) were measured in undiluted cell culture
upernatant samples using a Milliplex multiplex bead assay (see
nline supplement).
.11. Statistical analysis
Clinical data were collected in CRFs, subject diaries and labora-
ory records. The statistical analysis of the data was performed by JG
onsult, an independent Contract Research Organization in accor-
ance with a statistical analysis plan and GCP and ICH-guidelines
nd documented in the clinical trial report. Here we report safety
esults and safety analysis based on the statistical trial report which
as performed using SAS software (SAS®, Cary, NC 27513, USA,
ersion 9.2 TS Level 1M0) on Platform Windows XP PRO Version
.1.2600. Adverse events were evaluated descriptively.
Immunogenicity results shown here were analyzed at SSI and
UMC using Prism 6.04 for Windows (GraphPad Software, Inc., La
olla, CA 92037, USA). Change from baseline to each observed visit
ithin groups and comparisons between groups were compared
sing Kruskal–Wallis test with Dunn’s correction. No formal sample
ize calculation was performed in this trial. An alpha <0.05 was
onsidered signiﬁcant throughout the trial.
. Results
.1. Trial subjects
Of 49 screened subjects 38 were included in the clinical trial.
he safety population consisted of all included subjects. Mean
ges were 20.7, 22.2, 30.5, and 24.6 years in vaccination groups
, 2, 3 and 4, respectively, overall mean age of 24.9 years, ran-
ing from 18–51 years. Seven subjects (7 females) were vaccinated
ith 50 g H1 (no adjuvant), 10 subjects (2 male, 8 female) with
0 g H1 + 125/25 g CAF01 (low adjuvant group), 11 subjects (2
ale, 9 female) with 50 g H1 + 313/63 g CAF01 (intermediate
djuvant group) and ﬁnally, 10 subjects (1 male, 9 female) with
0 g H1 + 625/125 g CAF01 (high adjuvant group). A total of 34
ubjects were included in the per-protocol population and 7, 9, 10
nd 8 from groups 1, 2, 3 and 4, respectively, were included in the
mmunogenicity analysis (Fig. 1). Long-term visits, 150 weeks after
nitial enrolment, were successfully conducted for 31 out of the 32 (2014) 7098–7107
original 34 per protocol trial subjects; 7, 9, 9 and 6 from groups
1–4, respectively.
3.2. Safety results
All 38 subjects with at least one vaccination were included in
the safety analysis. No vaccine related serious or severe adverse
reactions occurred during the trial. Loco-regional injection site
reactions occurred more frequently in those given the CAF01-
adjuvanted antigen, and mainly included stiffness (deﬁned as
injection site movement impairment) and pain at the injection site
one day after the vaccinations (Table 1). Of note, these reactions
were not more frequent after the second vaccination and there
was no signiﬁcant difference between the three adjuvant doses.
In total, any local adverse reactions were distributed with 6 events
in 2 (29%) subjects in the non-adjuvanted group 1, 26 events in 10
(100%) subjects in group 2, 24 events in 9 (82%) subjects in group 3
and 26 events in 9 (90%) subjects in group 4. None of the subjects
required analgesics and all experienced full recovery within a max-
imum of 4 days. A small, cold nodule at the injection site was noted
in 1 subject in the intermediate CAF01 dose group 3. No signs of
attendant inﬂammation or local vesiculation, axillary lymphadeni-
tis or ﬁstula did occur, and the nodule had disappeared within one
week. One subject in group 4 (in concomitant treatment with tra-
madol) did not receive the second vaccination due to rash and itch
on knees, hips and elbows, as a relation to the trial vaccine could
not be ruled out. Three individuals observed reactivity at the TST
injection site after vaccination, two  were in the mid- and high-dose
adjuvant groups (reporting erythema and induration) and one was
in the group receiving H1 without adjuvant (reporting erythema
and swelling). A fourth individual observed erythema and indura-
tion at the site of the ﬁrst vaccination after the 2nd vaccination
(Table 1).
Systemic adverse reactions included headache, fatigue, malaise
and fever in one subject given antigen only. Extensive follow-
up of blood and urine parameters did not reveal any obvious
trends within or differences between the three vaccination groups,
or laboratory abnormalities with respect to change from base-
line that could be related to the vaccinations. In the two  subjects
who developed a transient fever the day after vaccination, a small
rise in C-reactive protein occurred that had subsided within a
week.
3.3. Immunogenicity results
3.3.1. IFN- ELISpot
Stimulation with H1, Ag85B and ESAT-6 gave rise to an increased
number of spot forming units (SFU) in all adjuvant groups (Fig. 2A
and B). The highest proportion of responders to vaccination was
seen in the low CAF01 group at week 32 and in the intermedi-
ate CAF01 group at week 32 and 52 (Fig. 2C). At this time point
median responses were 301 SFU/per million PBMC (inter quartile
range (IQR) 111–668 SFU) for H1; 308 SFU (IQR 108–558 SFU) for
Ag85B and 39 SFU (IQR 9.5–136 SFU) for ESAT-6, p < 0.05 (Fig. 2B).
No changes from baseline were seen in the non-adjuvant group at
any time points. Overall, there was  a clear trend in the adjuvant
groups that responses increased after the ﬁrst vaccination and that
a second vaccination further increased the magnitude of responses
(Fig. 2A).
3.3.2. Multiplex analysis of secreted biomarkers
To assess the breadth of the vaccine-induced immune memory,we performed an exploratory multiplex analysis of 14 cytokines
and chemokines in supernatants of 24 h H1 stimulated PBMCs. We
observed a broad induction of multiple cytokines and chemokines
at both weeks 14 and 32 for the three groups vaccinated with
J.T. van Dissel et al. / Vaccine 32 (2014) 7098–7107 7101
F d into
w col po
a
p
i
M
T
Iig. 1. Study overview and ﬂow chart. Overview of volunteers screened and include
hereas only those that received both vaccinations were included in the per-protodjuvanted H1, responses in the intermediate CAF01 group are
resented in Fig. 3 (all groups in supplementary Figure 1). The dom-
nating markers were Th1 associated (IFN-, TNF-, IP-10, MIG,
IP-1b and GM-CSF), but we also observed a substantial release of
able 1
Group 1 Group 2 
H1 only H1 + 125/25 g C
Safety  analysis set, n 7 10 
Local  adverse reactions; number of subjects (%), total number of reactions
Reactions at site of injection
Injection site stiffness 1 (14) 1 3 (30) 3
Injection site pain 0 (0) 0 10 (100) 15 
Injection site swelling 0 (0) 0 2 (20) 2 
Injection site erythema 0 (0) 0 2 (20) 2 
Injection site induration 0 (0) 0 1 (10) 1 
Injection site pruritus 0 (0) 0 1 (10) 1 
Injection site bruising 0 (0) 0 1 (10) 1 
Other  local reactions
Lymphadenopathy 0 (0) 0 1 (10) 1 
Reactions at site of tuberculin skin testing
Erythema 1 (14) 1b 0 (0) 0 
Induration 0 (0) 0 0 (0) 0 
Swelling 1 (14) 2b 0 (0) 0 
Reactions at site of ﬁrst vaccination
Erythema 1 (14) 1 0 (0) 0 
Induration 1 (14) 1 0 (0) 0 
Any  local adverse reaction 2 (29) 6 10 (100) 26 
Systemic adverse reactions; n (%), total number of reactions
Fatigue 2 (29) 3 1 (10) 1 
Malaise 0 (0) 0 0 (0) 0 
Pyrexia 1 (14) 1 0 (0) 0 
Rhinitis 1 (14) 1 0 (0) 0 
Musculoskeletal stiffness 0 (0) 0 0 (0) 0 
Myalgia 1 (14) 1 0 (0) 0 
Headache 1 (14) 1 1 (10) 1 
Pruritus 0 (0) 0 0 (0) 0 
Rash  pruritic 0 (0) 0 0 (0) 0 
Any  systemic adverse reaction 3 (43) 7 2 (20) 2 
njection site stiffness reactions (MedDRA PT term Injection site movement impairment) 
a One subject had erythema and induration at the 1st injection site after the 2nd vaccin
b Three subjects had erythema, induration and or swelling at the Tuberculin injection s the clinical trial. All volunteers vaccinated were included in the safety population,
pulation used for immunological analyses.IL-13, but not IL-4. IL-2, IL-10 and IL-17 followed the same kinetic
pattern, but levels were very low (<20 pg/ml) and failed to reach
signiﬁcance (Fig. 3 and data not shown). No clear pattern emerged
for VEGF, IL-22 and MCP-1 (supplementary Figure 1).
Group 3 Group 4
AF01 H1 + 313/63 g CAF01 H1  + 625/125 ug CAF01
11 10
9 (82) 13 7 (70) 8
2 (18) 2 5 (50) 6
2 (18) 2 4 (40) 5
1 (9) 1 3 (30) 3
1 (9) 1 0 (0) 0
0 (0) 0 1 (10) 2
0 (0) 0 0 (0) 0
1 (9) 1 0 (0) 0
1 (9) 2b,a 1 (10) 1b
1 (9) 2b,a 1 (10) 1b
0 (0) 0 0 (0) 0
0 (0) 0 0 (0) 0
0 (0) 0 0 (0) 0
9 (82) 24 9 (90) 26
0 (0) 0 3 (30) 3
0 (0) 0 2 (20) 3
0 (0) 0 0 (0) 0
0 (0) 0 0 (0) 0
1 (9) 1 0 (0) 0
0 (0) 0 0 (0) 0
1 (9) 1 2 (20) 3
1 (9) 1 1 (10) 1
0 (0) 0 1 (10) 1
3 (27) 4 4 (40) 11
were of mild intensity (easily tolerated) except for one of moderate intensity.
ation.
ite (of original PPD skin testing) after the 1st and/or 2nd vaccination.
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Fig. 2. IFN- spot forming units (SFUs) per 1 million PBMCs measured by ELISpot. (A) Healthy volunteers were given two  doses of intramuscular injection of 50 g of
H1  antigen without CAF01 adjuvant (n = 7), low dose CAF01 adjuvant (n = 9), intermediate dose CAF01 adjuvant (n = 10) or high dose CAF01 adjuvant (n = 8). Vaccinations
were  done at week 0 and week 8 and PBMC samples were collected at weeks 0, 1, 6, 9, 14, 32, 52 and 150 and stimulated with H1  protein. Interconnected dots represent
median, error bars interquartile range.  indicates vaccination, * indicates p < 0.05 compared to week 0 (Kruskal–Wallis, with Dunn’s multiple comparisons test). (B) Healthy
volunteers were given two  doses of intramuscular injection of 50 g of H1 antigen in intermediate dose CAF01 adjuvant (n = 10). Vaccinations were done at week 0 and
week  8 and PBMC samples were collected at week 32. PBMCs were stimulated with H1 protein or Ag85B or ESAT-6 peptide pools and IFN- producing spots quantiﬁed
using  ELISpot. Responses are presented as median error bars interquartile range. * indicates p < 0.05, **p < 0.005 compared to week 0 (Kruskal–Wallis, with Dunn’s multiple
comparisons test). (C) The proportion of responders to H1 stimulation was  deﬁned as the number of H1 induced IFN--producing spots greater than the mean + 2.5 SD of
unstimulated cells and was expressed as percentage of the group size.
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Fig. 3. Cytokine secretion in supernatants of 6 day H1 stimulated PBMCs. PBMCs were collected at baseline and at weeks 14 and 32 after two doses of intramuscular injection
of  50 g of H1 antigen. PBMCs were stimulated with H1 antigen for 6 days, supernatants were collected and cytokines and chemokines were measured using multiplex bead
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o  week 0 (Kruskal–Wallis, with Dunn’s multiple comparisons test).
.3.3. Flow cytometry
To further assess the long-term immunogenicity of H1:CAF01,
BMC samples at week 150 were analyzed by Intracellular ﬂow
ytometry. Compared to the non-adjuvant group, intermediate
nd high dose CAF01 groups had increased frequencies of Ag85B-
peciﬁc CD4 T-cells producing IFN- and/or IL-2 and/or TNF-
Fig. 4A). Moreover, intermediate and high dose CAF01 groups
nduced signiﬁcant TNF- production, but only the intermediate
AF01 group reached signiﬁcant levels of IL-2 (Fig. 4B) ESAT-6 spe-
iﬁc CD4 T-cells were seen in the adjuvant groups, but responses
ere not signiﬁcantly different from those in the non-adjuvant
roup. The most prevalent subset was IL-2/TNF-  double producing
D4 T-cells, and signiﬁcantly increased frequencies of these cells
ere seen in the intermediate and high adjuvant groups compared
o the non-adjuvant group (Fig. 4C). Responses were also detected
n the triple positive subset and TNF- single positive subset, but
either reached signiﬁcance. No signiﬁcant IL-17 responses to anti-
enic stimulation were detected (data not shown). No CD8 T-cell
esponses were observed following Ag85B or ESAT-6 stimulation
data not shown).
.3.4. Antibody responses
No statistically signiﬁcant changes from baseline were seen in
ny of the vaccination groups in IgG anti-Ag85B-ESAT-6 speciﬁc
ntibody titer (data not shown, methods in online supplement)..3.5. Quantiferon®-TB Gold conversion
QFT was performed at baseline at week 32, and 150 weeks after
he last vaccination. All subjects were negative before vaccination
as per the inclusion criteria) and none in the non-adjuvanted groupesponses are presented as individual measurements, * indicates p < 0.05 compared
became QFT positive. However introducing CAF01 adjuvant in the
vaccine caused 3 out of 8 (38%) individuals in the low CAF01 group
to convert to a positive test, 6 out of 10 (60%) in the intermediate
CAF01 group and 3 out of 8 (38%) in the high adjuvant group (Fig. 5).
All but two  of the QFT converters had reverted to negative at week
150. One QFT converter was lost to the extended follow up.
4. Discussion
This report describes the ﬁrst clinical trial in humans investigat-
ing the TB vaccine H1:CAF01, combining a new liposomal adjuvant
CAF01 with a well-deﬁned TB subunit vaccine antigen H1. In this
study, the vaccine was safe, well tolerated and generated long-
lasting (3 years) T-cell responses, as monitored by IFN- ELISpot,
intracellular cytokine staining and multiplex analysis of 14 secreted
cytokines and chemokines.
Two  vaccinations with H1:CAF01 did not lead to any serious
adverse reactions. All adverse events that were assessed as related
to the vaccination were mild or moderate and disappeared within
days. The main H1:CAF01-related adverse event was stiffness and
pain at the injection site, of mild to moderate severity, mostly
the day after administration of the vaccine. A mild to moderate
transient local reactogenicity of H1:CAF01 was  anticipated based
on the ﬁndings in nonclinical GLP toxicity studies and was also
observed in previous vaccination studies in humans with the H1
antigen [6,7,21]. The vaccine did not consistently affect hematolog-
ical or biochemical measurements. In conclusion, this clinical trial
found no safety concerns associated with the administration of the
CAF01-adjuvanted vaccine to healthy adults. As this was a phase
I trial, the limitation to this conclusion is the limited number of
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Fig. 4. Ag85B- and ESAT-6-speciﬁc CD4 responses in PBMCs collected at week 150 measured by ﬂow cytometry. (A) Long-term visits at week 150 after vaccinations were
successfully conducted for 31 out of the original 34 per protocol trial subjects; 7, 9, 9 and 6 from groups 1–4, respectively. PBMCs were isolated and frequencies of IFN-,
IL-2  or TNF- producing CD4+CD154+T-cells were measured after stimulation with Ag85B or ESAT-6 peptide pools. Responses are presented as box and whiskers, wherein
the  box represents median and interquartile range, whiskers range. For each individual, background values (DMSO) were subtracted. Kruskal–Wallis, with Dunn’s multiple
comparisons test, * indicates p < 0.05 compared to the no adjuvant group. (B) Frequency of IFN- (left), IL-2 (middle) or TNF- (right) producing CD4+CD154+T-cells were
measured after stimulation of week 150 PBMCs with Ag85B or ESAT-6 peptide pools. Responses are presented as box and whiskers, wherein the box represents median and
interquartile range, whiskers range. For each individual, background values (DMSO) were subtracted. Kruskal–Wallis, with Dunn’s multiple comparisons test, * indicates
p  < 0.05 compared to the no adjuvant group. (C) Patterns of single or combined production of IFN-, IL-2 or TNF- by CD154+CD4+T-cells after stimulation of with Ag85B
peptide  pool are shown. The median frequency for each cytokine-producing cell subset is represented by the horizontal line, the interquartile range by the box, and the range
b Krusk
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cy  the whiskers. For each individual, background values (DMSO) were subtracted. 
he  no adjuvant group.
ubjects, and we can exclude with certainty only frequently occur-
ing adverse reactions. On the other hand, the lack of any signiﬁcant
eactogenicity despite the immunogenicity of the CAF01-
djuvanted vaccine is important, given the paucity of effective
uman adjuvants for the induction of cell-mediated immune
esponses [22].Successful vaccination against TB disease would be a major step
o diminish TB disease burden and spread, however an important
hallenge remains to determine vaccine efﬁcacy. Despite signiﬁ-
ant investments in the search for an accurate surrogate endpointal–Wallis, with Dunn’s multiple comparisons test, * indicates p < 0.05 compared to
for protection against TB disease, no such biomarker has been
identiﬁed. However, there is general consensus that an effective
TB vaccine needs to be able to elicit at least a Th1 cell response
which is essential for bacterial containment [23]. Importantly,
due to the nature of the pathogen, a novel vaccine will need to
induce long-lived protection, most likely through the induction of
central memory T (TCM) cells. Whereas IFN- production is the
classical hallmark of Th1 cell responses and for many years has
been used as the primary measurement in TB vaccine clinical test-
ing, CD4 T-cells with a regenerative potential are typically IL-2
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Fig. 5. Quantiferon TB Gold in tube (QFT) IFN- responses after vaccination with H1 alone and adjuvanted with low, intermediate and high CAF01 dose. Whole blood was
collected in QFT blood collection tubes at baseline, week 52 and week 150 and incubated 16–24 h. Plasma was isolated by centrifugation and IFN- was determined using
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dLISA. Responses were classiﬁed as positive if the antigen-speciﬁc level (Ag-Nil) wa
ositive and TCM are usually functionally deﬁned by the expression
f IL-2 and CCR7/CD62L. Two vaccinations of H1:CAF01 induced
 strong long-lasting cellular immune response to H1 and its two
ntigen components ESAT-6 and Ag85B. Responses were strongest
o the Ag85B antigen, as observed previously also for H1:IC31
6,7]. Measured by IFN- ELISpot, the vaccine led to increased
esponses at subsequent visits which were sustained also after 150
eeks, demonstrating a clear and long-term vaccine take in all
hree adjuvanted vaccine groups, but not in the non-adjuvanted
roup, as observed previously also for H1:IC31 [6,7]. This pattern
as conﬁrmed by the broad induction of mainly Th1 associated
ytokines (IFN-, IL-2, TNF-, GM-CSF) and chemokines (MIG, IP-
0 and MIP-1).  Three years after vaccination, the intermediate
nd high H1:CAF01 dose groups showed signiﬁcant numbers of
ntigen-speciﬁc CD4 T-cells secreting IL-2 and TNF-, consistent
ith a central memory differentiation state, ready to become effec-
or T-cells if required [24]. These results are in line with two
ecent and closely related TB vaccine trials investigating H1:IC31
n HIV-infected individuals, and H56:IC31 in healthy individuals
ith or without latent TB (Klaus Reiter, Gavin Churchyard, Thomas
criba, personal communication), and recent results from a phase
/II trial of the subunit vaccine M72  adjuvanted in the liposome
ased AS01E [25]. These results underpin that estimates of vaccine
mmunogenicity based on IFN- detection alone will miss other
elevant vaccine-induced immune responses. The prolonged main-
enance of immune competence elicited by the CAF01-adjuvanted
ubunit vaccine is in good agreement with observations from
ouse studies [11,12], and suggests that the adjuvant, likely
hrough establishment of an antigen depot and subsequent slow
elease and targeting of dendritic cells [16], may  have particu-
ar abilities to maintain immune memory [26]. In this regard, it
s interesting to note that the development of immune proﬁles
iffer markedly between viral vectored vaccines and adjuvanted5 IU/ml.
subunit vaccines with the latter having a slowly developing
response dominated by IL-2/TNF-  double positive T-cells and with
no tendency of a waned response over the three years observa-
tion time. Although MVA85A induces highly durable Th1 responses,
peak responses were observed already 7 days post-vaccination [27]
and with triple and double positive TNF-/IFN- T-cells resembling
a more effector-memory proﬁle [28]. Whether this difference has
any inﬂuence on the overall protective capability remains to be
seen.
Signiﬁcant amounts of IL-13 were also found in the intermedi-
ate and high dose CAF01 groups. IL-13 is traditionally associated
with Th2-type immune responses and together with IL-4 involved
in inﬂammatory disorders, however, a number of recent ﬁndings
suggest a more complex lineation. Gallo and Katzman identiﬁed
IL-13 producing CD4 T-cells in mice co-expressing IFN- and IL-
17 generated both during autoimmune diseases but also upon
immunization [29]. Although the induction of IL-13 in human vac-
cine trials is a relatively unexplored ﬁeld, IL-13 responses has also
been observed in volunteers receiving the Th1-promoting adjuvant
MPL® [30] and synthetic HIV-1 peptides coupled to a palmytoil tail
was found to induce both IFN- and IL-13 in a phase II trial [31].
These novel data show that IL-13 is an integrated component of a
vaccine-induced Th1/Th17 response and an important role of IL-
13 could be to down-regulate the vigorous inﬂammatory response
induced by these novel generation adjuvants. We  recently iden-
tiﬁed IL-13 secretion after vaccination with CAF01-based subunit
vaccines in mice and the cellular origin and the regulatory role in
balancing Th1/Th17 responses is currently under exploration (Diet-
rich, unpublished).This trial demonstrated promising immunogenicity results,
a good safety proﬁle and no dose dependent adverse events.
Immunogenicity data suggests that the intermediate and high dose
of adjuvant induced superior TCM proﬁle, however this phase 1
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afety trial was not designed for ﬁrm conclusion on dose selection.
f these characteristics of CAF01 are conﬁrmed for other disease
argets, this adjuvant would be among the ﬁrst candidates capa-
le of inducing long-term memory cellular immune response in
umans. This property is unique and not shared with currently
pproved adjuvants like aluminum salts and MF59, both of which
rimarily promote a Th2 or humoral immune response [22,32–34].
ased on results from animal models we expected CAF01 adju-
anted vaccines to also induce antibody responses to the vaccine
ntigen, however herein two vaccinations with H1:CAF01 did not
nduce signiﬁcant IgG responses. Similarly, H1 in IC31® also failed
o induce signiﬁcant H1-speciﬁc IgG levels after two injections. We
ecently found speciﬁc IgG after a third administration of H56:IC31
Hoff, Andersen, unpublished observation), suggesting that a third
ose is required to induce IgG responses to this particular vaccine
ntigen in humans.
ESAT-6 is included in Interferon gamma  release assay (IGRA)
iagnostic test kits. In the present trial, similar to previous
1:IC31® trials, vaccination was associated with a transient con-
ersion of the QFT in about half of the vaccinated subjects. Induction
f ESAT-6 speciﬁc immune responses by vaccination with an ESAT-
-containing vaccine may  very well interfere with current ESAT-6
ased diagnostics. However, this may  not pose a major diagnostic
roblem, as IGRAs are indicated in low endemic settings and TB
accines will mainly be used in high endemic settings [35].
In conclusion, we report the ﬁrst in man  studies of the CAF01
djuvant and demonstrate its safety in a phase I trial. Vaccination
ith CAF01 together with the H1 fusion protein resulted in long
asting T-cell immunity characterized by mainly IL-2 and TNF-
roducing T-cells indicating that CAF01 is of relevance for future
uman vaccination studies.
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